TITLE

New Therapeutic Targets for Drug Design Against Trypanosoma cruzi, Advances and Perspectives

AUTHOR(S)
Rivera, Gildardo; Bocanegra-García, Virgilio; Ordaz-Pichardo, Cynthia; Nogueda-Torres, Benjamin; Monge, Antonio
PUB. DATE
September 2009
SOURCE
Current Medicinal Chemistry;Sep2009, Vol. 16 Issue 25, p3286
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chagas disease is one of the most important parasitic diseases in Latin America, affecting16 to 18 million people. Nifurtimox and Benznidazol are drugs that are commonly used in its treatment; however, these drugs produce several adverse reactions and are not effective in the chronic phase of the disease. Therefore, the design, synthesis, and biological evaluation of new compounds with potential activity against Trypanozoma cruzi are of great importance. We review six proteins involved in the biochemical metabolism of Trypanosoma cruzi that have recently been studied as potential targets for designing new drugs for Chagas disease. These are farnesyl pyrophosphate synthase, trans-sialidase, cruzain cystein protease, trypanothione reductase, glucose 6-phosphate-dehydrogenase, glyceraldehyde 3-phosphatedehydrogenase, and α-hydroxy acid dehydrogenase. We also review the advances of compounds recently designed based on structure-activity, and the perspectives of new compounds that inhibit these therapeutic targets.
ACCESSION #
43901470

 

Related Articles

  • VNI Cures Acute and Chronic Experimental Chagas Disease. Villalta, Fernando; Dobish, Mark C.; Nde, Pius N.; Kleshchenko, Yulia Y.; Hargrove, Tatiana Y.; Johnson, Candice A.; Waterman, Michael R.; Johnston, Jeffrey N.; Lepesheva, Galina I. // Journal of Infectious Diseases;Aug2013, Vol. 208 Issue 3, p504 

    Chagas disease is a deadly infection caused by the protozoan parasite Trypanosoma cruzi. Afflicting approximately 8 million people in Latin America, Chagas disease is now becoming a serious global health problem proliferating beyond the traditional geographical borders, mainly because of human...

  • A Functional Network of Intramolecular Cross-Reacting Epitopes Delays the Elicitation of Neutralizing Antibodies to Trypanosoma cruzi trans-Sialidase. Pitcovsky, Tamara A.; Buscaglia, Carlos A.; Mucci, Juan; Campetella, Oscar // Journal of Infectious Diseases;8/1/2002, Vol. 186 Issue 3, p397 

    Trypanosoma cruzi trans-sialidase (TS) constitutes a key molecule in both the establishment of the infection and in the development of pathologic abnormalities associated with Chagas disease. Several cross-reactive epitopes located in its catalytic region were previously identified. In the...

  • The Immune Response to Trypanosoma cruzi : Role of Toll-Like Receptors and Perspectives for Vaccine Development. Rodrigues, Mauricio M.; Oliveira, Ana Carolina; Bellio, Maria // Journal of Parasitology Research;2012, p1 

    In the past ten years, studies have shown the recognition of Trypanosoma cruzi-associated molecular patterns by members of the Toll-like receptor (TLR) family and demonstrated the crucial participation of different TLRs during the experimental infection with this parasite. In the present review,...

  • Encefalitis chagásica: una complicación tardía postrasplante cardiaco. De Castro Assis, Alfredo Fernández; Berdugo Sánchez, Alejandra; Cortés, Norma Lucía // Universitas Médica;ene-mar2008, Vol. 49 Issue 1, p112 

    Chagas' disease, also called American trypanosomiasis, is a human tropical parasitic disease that occurs in the Americas, particularly in South America. Its pathogenic agent is a flagellate protozoan named Trypanosoma cruzi, which very rarely involves the central nervous system. Few cases have...

  • Prevalence of Trypanosoma cruzi infection in blood donors in El Salvador between 2001 and 2011. Emi Sasagawa; Guevara de Aguilar, Ana Vilma; Hernández de Ramírez, Marta Alicia; Romero Chévez, José Eduardo; Jun Nakagawa; Cedillos, Rafael Antonio; Chizuru Misago; Kiyoshi Kita // Journal of Infection in Developing Countries;Aug2014, Vol. 8 Issue 8, p1029 

    Introduction: El Salvador is regarded as a highly endemic country for Chagas disease, as evidenced by the relatively high estimated positive serology rate for Trypanosoma cruzi among blood donors. This study aimed to identify the factors contributing to this high rate by analyzing changes in T....

  • Trypanosome Prereplication Machinery: A Potential New Target for an Old Problem. Calderano, Simone Guedes; de Melo Godoy, Patricia Diogo; da Cunha, Julia Pinheiro Chagas; Elias, Maria Carolina // Enzyme Research;2011, p1 

    Approximately ten million people suffer from Chagas disease worldwide, caused by Trypanosoma cruzi, with the disease burden predominately focused in Latin America. Sleeping sickness is another serious health problem, caused by Trypanosoma brucei, especially in sub-Saharan countries....

  • Trypanosoma cruzi Dihydrolipoamide Dehydrogenase as Target for Phenothiazine Cationic Radicals. Effect of Antioxidants. Guti�rrez-Correa, Jos� // Current Drug Targets;Sep2006, Vol. 7 Issue 9, p1155 

    Myeloperoxidase (MPO), myoglobin (Mb) and horseradish peroxidase (HRP), catalyzed the generation of radical-cations by one-electron oxidation of phenothiazines (PTZ). The transient formation of these radicals (PTZ+ .) was confirmed by ESR and optical spectroscopy. These species are reactive...

  • Chagas Disease: 'Aids of the Americans'? Gatson, Brittany // Tennessee Tribune;6/14/2012, Vol. 23 Issue 25, p4B 

    The article offers information about the Chagas' disease, which is caused by a parasite called Trypanosoma cruzi.

  • Intruder in the Heart. Panosian, Claire // Discover;Dec98, Vol. 19 Issue 12, p38 

    Deals with the infection known as Chagas' disease. Single-celled protozoan called Trypanosoma cruzi; Major cause of cardiac death in young and middle-aged people in Central and South America.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics